Mass Spectrometry in Non-Small Cell Lung Cancer Patients for prediction of Clinical Outcome after Tr

• 作 者: 杨邵瑜;陈雪琴;余捷凯;潘月龙;马胜林;
• 机 构: 南京医科大学附属杭州医院(浙江省杭州市第一人民医院)肿瘤内科,310006
• 出 处: 2015医学前沿论坛暨第十四届全国肿瘤药理与化疗学术会议
• 发表日期: 2015年期

　　Objective This study aimed to identify potential serum biomarkers to classify advanced NSCLC patients for clinical outcome after treat with EGFR-TKIs.Methods We collected 61 samples, used the integrated approach of MALDI-TOF/TOF-MS, Protein Chip Data Analyze System and SVM tools to compare the protein spectra of EGFR-TKI resistant patients with EGFR-TKI sensitive patients.Results Among the 61 patients in the study, none had a complete response,18 patients had a partial response (29.5%);18 patients had a stable disease more than 6 months(29.5%) and 25 patients had a progressive disease or stable disease less than 6 months(41%).There were 36 patients with resistance to EGFR-TKI and 25 patients with EGFR-TKI sensitivity.